Tretinoin
- Generic Name
- Tretinoin
- Brand Names
- Altreno, Atralin, Biacna, Refissa, Renova, Retin-A, Stieva-A, Tri-luma, Twyneo, Veltin, Vesanoid, Ziana
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28O2
- CAS Number
- 302-79-4
- Unique Ingredient Identifier
- 5688UTC01R
- Background
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, ...
- Indication
Oral tretinoin is indicated for induction of remission in adults and pediatric patients one year of age and older with acute promyelocytic leukemia (APL), characterized by the presence of t(15;17) translocation or presence of PML/RARα gene expression and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-base...
- Associated Conditions
- Acne Vulgaris, Alopecia, Cornification and dystrophic skin disorders, FAB classification M3 Acute promyelocytic leukemia, Fine Wrinkles, Photodamaged Skin, Skin hyperpigmentation, Keratinization disorders of the feet, Keratinization disorders of the hand, Moderate Melasma, Mottled hyperpigmentation, Severe Melasma, Severe, recalcitrant Cystic acne, Tactile roughness of facial skin
- Associated Therapies
- -
Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
- Conditions
- Locations
- 🇩🇪
Carl - Thiem - Klinkum Cottbus, Cottbus, Germany
🇩🇪Klinikum Lippe - Detmold, Detmold, Germany
🇩🇪Praxis am Evangelischen Krankenhaus Bethanien, Iserlohn, Germany
Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer
- Conditions
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Registration Number
- NCT00005863
- Locations
- 🇬🇧
Birmingham Heartlands Hospital, Birmingham, England, United Kingdom
Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)
- Conditions
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.